Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, H…
Drug Manufacturers - General
US, Indianapolis [HQ]
Insiders
Transactions
Track non-derivative insider transactions.
i = Indirect Ownership
d = Direct Ownership
cs = Common Stock
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$16,191,301
d
cs
10% Holder
|
12/16/24 |
A
|
19,042 x $779.00 = $14,833,718.00 |
Footnotes
#1 At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
|
|||
|
$3,032,146
d
cs
10% Holder
|
12/16/24 |
A
|
12,409 x $779.00 = $9,666,611.00 |
Footnotes
#1 At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
|
|||
|
$1,878,965
d
cs
10% Holder
|
12/16/24 |
A
|
1,273 x $779.00 = $991,667.00 |
Footnotes
#1 At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
|
|||
|
$54,689,496
d
cs
10% Holder
|
12/16/24 |
A
|
15,083 x $779.00 = $11,749,657.00 |
Footnotes
#1 At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
|
|||
|
$2,532,931
d
cs
10% Holder
|
12/16/24 |
A
|
1,273 x $779.00 = $991,667.00 |
Footnotes
#1 At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
|
|||
Get PRO Today
With PRO you will unlock 118 more insider transactions for Eli Lilly and Company
Statistics
Sample Size: 123 Transactions
Sale (S)
34,290 Shares
7.32%
Buy (P)
0 Shares
0.00%
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Alvarez Ralph Director
- Ashkenazi Anat EVP & CFO
- Baicker Katherine Director
- Brooks Gordon J. Interim CFO, Group VP
- Dozier Eric EVP, HR & Diversity
- Fyrwald J Erik CEO
- Hakim Anat EVP, GC & Secretary
- Hedley Mary Lynne Director
- Hernandez Edgardo EVP & Pres., Mfg. Operations
- Jackson Jamere Director
- Johnson Kimberly H Director
- Jonsson Patrik EVP&Pres, LLY Dia&Obe, LLY USA
- Kaelin William G Jr Director
- Luciano Juan R President & CEO
- Moeller Jon R Director
- Montarce Lucas EVP & CFO
- Norton Johna EVP, Global Quality
- Rau Diogo EVP & CIDO
- Ricks David A President, Chair, and CEO
- Seymour Melissa EVP, Global Quality
- Skovronsky Daniel EVP, CSO & Pres. LRL & LLY Imm
- Sulzberger Gabrielle Director
- Van Naarden Jacob EVP & Pres., Lilly Oncology
- Walker Karen Director
- Weems Alonzo EVP, ERM & CECO
- White Anne E. EVP & Pres, Lilly Neuroscience
- Yuffa Ilya EVP & President, LLY Int'l
- Zakrowski Donald A SVP, Finance, & CAO
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Alvarez Ralph Director
- Ashkenazi Anat EVP & CFO
- Baicker Katherine Director
- Brooks Gordon J. Interim CFO, Group VP
- Dozier Eric EVP, HR & Diversity
- Fyrwald J Erik CEO
- Hakim Anat EVP, GC & Secretary
- Hedley Mary Lynne Director
- Hernandez Edgardo EVP & Pres., Mfg. Operations
- Jackson Jamere Director
- Johnson Kimberly H Director
- Jonsson Patrik EVP&Pres, LLY Dia&Obe, LLY USA
- Kaelin William G Jr Director
- Luciano Juan R President & CEO
- Moeller Jon R Director
- Montarce Lucas EVP & CFO
- Norton Johna EVP, Global Quality
- Rau Diogo EVP & CIDO
- Ricks David A President, Chair, and CEO
- Seymour Melissa EVP, Global Quality
- Skovronsky Daniel EVP, CSO & Pres. LRL & LLY Imm
- Sulzberger Gabrielle Director
- Van Naarden Jacob EVP & Pres., Lilly Oncology
- Walker Karen Director
- Weems Alonzo EVP, ERM & CECO
- White Anne E. EVP & Pres, Lilly Neuroscience
- Yuffa Ilya EVP & President, LLY Int'l
- Zakrowski Donald A SVP, Finance, & CAO